Could RNA editing therapies reshape precision medicine over the next decade?

What makes RNA editing different from DNA editing—and why that matters for precision medicine?

RNA editing works by changing the instructions cells use to make proteins, without altering the underlying DNA blueprint. This is a fundamental shift from gene therapies that permanently modify the genome. Because RNA molecules are constantly produced and degraded, an RNA edit is reversible—if a treatment causes problems, you can stop it. This safety feature is especially attractive for conditions where permanent changes carry unknown long-term risks, such as in the brain or during development. A 2023 review of RNA-targeting therapies for neurological diseases notes that this reversibility allows for 'flexible therapies' that can be adjusted over time [2].

The precision of RNA editing is also improving rapidly. A 2024 study demonstrated a technique called 'wobble-enhanced circular CLUSTER guide RNA' that achieved up to 87% correction of a disease-causing mutation in the Mecp2 gene in cell culture, and in a mouse model of Rett syndrome, it restored functional MeCP2 protein in the central nervous system with editing yields of up to 19% and excellent control over unintended edits [1]. This level of precision—where the edit happens exactly where intended, with minimal 'bystander' changes—is critical for clinical use. The study found that using G•U wobble base pairs at specific sites effectively suppressed off-target editing while maintaining high on-target efficiency [1].

Where is the evidence strongest that RNA editing can actually treat disease?

The strongest evidence comes from two areas: neurological disorders and inherited retinal diseases. For neurological conditions, RNA-targeting therapies are already in clinical use. Antisense oligonucleotides (ASOs)—a type of RNA-targeting drug—have six market-approved drugs for conditions like spinal muscular atrophy and Duchenne muscular dystrophy, and several more are in late-stage trials for Huntington's disease and ALS [2]. A 2023 review reports that one ASO for ALS (Tofersen) has even been filed for FDA approval [2]. These are not yet 'editing' in the strict sense (they mostly silence or splice-modify RNA), but they prove that RNA-level interventions can be safe and effective in humans.

For true RNA base editing—changing one RNA letter to another—the most advanced work uses the body's own ADAR enzymes. A 2026 review on inherited retinal diseases (IRDs) describes multiple guide RNA formats (linear, circular, chemically modified) that recruit ADAR to correct disease-causing mutations at the RNA level [5]. The same review notes that ADAR enzymes are naturally expressed in retinal tissue, making the eye a promising target for this approach [5]. In a 2024 study, virus-delivered guide RNAs alone (without any foreign enzyme) achieved functional protein restoration in a mouse model of Rett syndrome, a severe neurological disorder [1]. This is significant because it avoids introducing foreign proteins that could trigger immune responses.

What are the biggest challenges that could slow down RNA editing's impact?

Despite the promise, several hurdles remain. Delivery is the most stubborn problem: getting RNA editing tools to the right cells in the body, especially outside the liver. A 2025 review of RNA therapeutics notes that 'effective delivery to extrahepatic tissues' is a critical challenge [4]. Most current delivery systems (like lipid nanoparticles) naturally accumulate in the liver, which is fine for liver diseases but not for brain, eye, or muscle disorders. For neurological diseases, the blood-brain barrier blocks most large molecules. The 2023 review points out that while viral vectors can deliver guide RNAs to the brain, they are not suitable for ASOs or siRNAs, which require repeated injections [2].

Off-target effects are another concern. CRISPR-Cas13 systems, which can cut RNA, have shown 'collateral activity'—accidentally cleaving non-target RNAs. A 2023 review reports a study where CRISPR-CasRx targeting a gene called SIK1 was fatal in mice due to collateral cleavage of ribosomal RNA, not due to the intended target [2]. This highlights the need for careful regulation of enzyme levels. ADAR-based editing is considered safer because it uses the body's own enzymes, but its efficiency can be lower, and it is currently limited to correcting A-to-G (or C-to-U) mutations, which covers only a subset of disease-causing variants [2][5]. A 2025 review also flags immune activation, manufacturing scalability, and the need for robust regulatory frameworks as key barriers to broad clinical adoption [4].

About These Sources

This answer is built on 5 peer-reviewed studies — published from 2023 to 2026, 4 from 2024 or later, 4 in Q1 journals — selected as the most relevant from 5 studies that passed quality screening, drawn from 69 papers retrieved from a database of over 500 million.

Sources used in this answer

Related research questions